1
|
Huang LS, Kotha SR, Avasarala S, VanScoyk M, Winn RA, Pennathur A, Yashaswini PS, Bandela M, Salgia R, Tyurina YY, Kagan VE, Zhu X, Reddy SP, Sudhadevi T, Punathil-Kannan PK, Harijith A, Ramchandran R, Bikkavilli RK, Natarajan V. Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. J Biol Chem 2020; 295:13393-13406. [PMID: 32732285 DOI: 10.1074/jbc.ra120.012680] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Revised: 07/15/2020] [Indexed: 02/06/2023] Open
Abstract
Lysocardiolipin acyltransferase (LYCAT), a cardiolipin (CL)-remodeling enzyme, is crucial for maintaining normal mitochondrial function and vascular development. Despite the well-characterized role for LYCAT in the regulation of mitochondrial dynamics, its involvement in lung cancer, if any, remains incompletely understood. In this study, in silico analysis of TCGA lung cancer data sets revealed a significant increase in LYCAT expression, which was later corroborated in human lung cancer tissues and immortalized lung cancer cell lines via indirect immunofluorescence and immunoblotting, respectively. Stable knockdown of LYCAT in NSCLC cell lines not only reduced CL and increased monolyso-CL levels but also reduced in vivo tumor growth, as determined by xenograft studies in athymic nude mice. Furthermore, blocking LYCAT activity using a LYCAT mimetic peptide attenuated cell migration, suggesting a novel role for LYCAT activity in promoting NSCLC. Mechanistically, the pro-proliferative effects of LYCAT were mediated by an increase in mitochondrial fusion and a G1/S cell cycle transition, both of which are linked to increased cell proliferation. Taken together, these results demonstrate a novel role for LYCAT in promoting NSCLC and suggest that targeting LYCAT expression or activity in NSCLC may provide new avenues for the therapeutic treatment of lung cancer.
Collapse
Affiliation(s)
- Long Shuang Huang
- Department of Pharmacology, University of Illinois, Chicago, Illinois, USA
| | - Sainath R Kotha
- Department of Pharmacology, University of Illinois, Chicago, Illinois, USA
| | | | - Michelle VanScoyk
- Department of Medicine, University of Illinois, Chicago, Illinois, USA
| | - Robert A Winn
- Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
| | - Arjun Pennathur
- Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | | | - Mounica Bandela
- Department of Medicine, University of Illinois, Chicago, Illinois, USA
| | - Ravi Salgia
- Beckman Research Institute, City of Hope, Los Angeles, California, USA
| | - Yulia Y Tyurina
- Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Valerian E Kagan
- Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; Department of Chemistry, Pharmacology, and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; Laboratory of Navigational Redox Lipidomics, I. M. Sechenov Moscow State Medical University, Moscow, Russia
| | - Xiangdong Zhu
- Center for Cardiovascular Research and Department of Emergency Medicine, University of Illinois, Chicago, Illinois, USA
| | - Sekhar P Reddy
- Department of Pediatrics, University of Illinois, Chicago, Illinois, USA
| | - Tara Sudhadevi
- Department of Pediatrics, University of Illinois, Chicago, Illinois, USA
| | | | - Anantha Harijith
- Department of Pediatrics, University of Illinois, Chicago, Illinois, USA
| | | | | | - Viswanathan Natarajan
- Department of Pharmacology, University of Illinois, Chicago, Illinois, USA; Department of Medicine, University of Illinois, Chicago, Illinois, USA.
| |
Collapse
|